Phaseline

Targets › TNFRSF1B

TNFRSF1B (Tumor necrosis factor receptor superfamily member 1B): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Hematology.

Receptor for TNF/TNFSF2 and LTA/TNFSF1, which activates the tumor necrosis factor-mediated (TNF) signaling pathway upon ligand-binding. Has high affinity for TNFSF2/TNF and approximately 5-fold lower affinity for LTA/TNFSF1. (UniProt, P20333)

Open in Phaseline: the race on TNFRSF1B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sichuan Clover BiopharmaceuticalsSCB-219M
TNF receptor II-Fc fusion protein with TPO mimetic peptide
TNFRSF1B, THPOPhase 1Chemotherapy-induced Thrombocytopenia (CIT)–

Conditions

Chemotherapy-induced Thrombocytopenia (CIT) (1)

Modalities

protein or peptide (1)

Companies

Sichuan Clover Biopharmaceuticals (1)

Related targets

THPO (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.